|
1
|
Anwanwan D, Singh SK, Singh S, Saikam V
and Singh R: Challenges in liver cancer and possible treatment
approaches. Biochim Biophys Acta Rev Cancer. 1873:1883142020.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Singh SP, Arora V, Madke T and Sarin SK:
Hepatocellular carcinoma-southeast asia updates. Cancer J.
29:259–265. 2013. View Article : Google Scholar
|
|
3
|
Mazzaferro V, Citterio D, Bhoori S,
Bongini M, Miceli R, De Carlis L, Colledan M, Salizzoni M,
Romagnoli R, Antonelli B, et al: Liver transplantation in
hepatocellular carcinoma after tumour downstaging (XXL): A
randomised, controlled, phase 2b/3 trial. Lancet Oncol. 21:947–956.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Reig M, Forner A, Rimola J, Ferrer-Fàbrega
J, Burrel M, Garcia-Criado Á, Kelley RK, Galle PR, Mazzaferro V,
Salem R, et al: BCLC strategy for prognosis prediction and
treatment recommendation: The 2022 update. J Hepatol. 76:681–693.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wong TC, Lee VH, Law AL, Pang HH, Lam KO,
Lau V, Cui TY, Fong AS, Lee SW, Wong EC, et al: Prospective study
of stereotactic body radiation therapy for hepatocellular carcinoma
on waitlist for liver transplant. Hepatology. 74:2580–2594. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tang W, Chen Z, Zhang W, Cheng Y, Zhang B,
Wu F, Wang Q, Wang S, Rong D, Reiter FP, et al: The mechanisms of
sorafenib resistance in hepatocellular carcinoma: Theoretical basis
and therapeutic aspects. Signal Transduct Target Ther. 5:872020.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Su X, Li Y, Ren Y, Cao M, Yang G, Luo J,
Hu Z, Deng H, Deng M, Liu B and Yao Z: A new strategy for
overcoming drug resistance in liver cancer: Epigenetic regulation.
Biomed Pharmacother. 176:1169022024. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kudo M, Finn RS, Qin S, Han KH, Ikeda K,
Piscaglia F, Baron A, Park JW, Han G, Jassem J, et al: Lenvatinib
versus sorafenib in first-line treatment of patients with
unresectable hepatocellular carcinoma: A randomised phase 3
non-inferiority trial. Lancet. 391:1163–1173. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux
M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, et al: Atezolizumab
plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J
Med. 382:1894–1905. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang Z, Wang Y, Gao P and Ding J: Immune
checkpoint inhibitor resistance in hepatocellular carcinoma. Cancer
Lett. 555:2160382023. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ostroverkhova D, Przytycka TM and
Panchenko AR: Cancer driver mutations: Predictions and reality.
Trends Mol Med. 29:554–566. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pirozzi CJ and Yan H: The implications of
IDH mutations for cancer development and therapy. Nat Rev Clin
Oncol. 18:645–661. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shahbandi A, Nguyen HD and Jackson JG:
TP53 mutations and outcomes in breast cancer: Reading beyond the
headlines. Trends Cancer. 6:98–110. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Prior IA, Hood FE and Hartley JL: The
frequency of ras mutations in cancer. Cancer Res. 80:2969–2974.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Timar J and Kashofer K: Molecular
epidemiology and diagnostics of KRAS mutations in human cancer.
Cancer Metastasis Rev. 39:1029–1038. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Herzog SK and Fuqua SAW: ESR1 mutations
and therapeutic resistance in metastatic breast cancer: Progress
and remaining challenges. Br J Cancer. 126:174–186. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Calderaro J, Couchy G, Imbeaud S, Amaddeo
G, Letouzé E, Blanc JF, Laurent C, Hajji Y, Azoulay D, Bioulac-Sage
P, et al: Histological subtypes of hepatocellular carcinoma are
related to gene mutations and molecular tumour classification. J
Hepatol. 67:727–738. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang P, Song Q, Ren J, Zhang W, Wang Y,
Zhou L, Wang D, Chen K, Jiang L, Zhang B, et al: Simultaneous
analysis of mutations and methylations in circulating cell-free DNA
for hepatocellular carcinoma detection. Sci Transl Med.
14:eabp87042022. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Calderaro J, Ziol M, Paradis V and
Zucman-Rossi J: Molecular and histological correlations in liver
cancer. J Hepatol. 71:616–630. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Loescher CM, Hobbach AJ and Linke WA:
Titin (TTN): From molecule to modifications, mechanics, and medical
significance. Cardiovasc Res. 118:2903–2918. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ceyhan-Birsoy O, Agrawal PB, Hidalgo C,
Schmitz-Abe K, DeChene ET, Swanson LC, Soemedi R, Vasli N,
Iannaccone ST, Shieh PB, et al: Recessive truncating titin gene,
TTN, mutations presenting as centronuclear myopathy. Neurology.
81:1205–1214. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kellermayer D, Smith JE III and Granzier
H: Titin mutations and muscle disease. Pflugers Arch. 471:673–682.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Djulbegovic MB, Uversky VN, Karp CL and
Harbour JW: Functional impact of titin (TTN) mutations in ocular
surface squamous neoplasia. Int J Biol Macromol. 195:93–101. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gomes FC, Figueiredo ERL, Araújo EN,
Andrade EM, Carneiro CDL, Almeida GM, Dias HAAL, Teixeira LIB,
Almeida MT, Farias MF, et al: Social, genetics and
histopathological factors related to titin (TTN) gene mutation and
survival in women with ovarian serous cystadenocarcinoma:
Bioinformatics analysis. Genes (Basel). 14:10922023. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Han X, Chen J, Wang J, Xu J and Liu Y: TTN
mutations predict a poor prognosis in patients with thyroid cancer.
Biosci Rep. 42:BSR202211682022. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kodali N, Alomary S, Bhattaru A, Eldaboush
A, Schwartz RA and Lipner SR: Gender and melanoma subtype-based
prognostic implications of MUC16 and TTN co-occurrent mutations in
melanoma: A retrospective multi-study analysis. Cancer Med.
13:e701992024. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xue D, Lin H, Lin L, Wei Q, Yang S and
Chen X: TTN/TP53 mutation might act as the predictor for
chemotherapy response in lung adenocarcinoma and lung squamous
carcinoma patients. Transl Cancer Res. 10:1284–1294. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu Z, Zhao X, Wang R, Tang X, Zhao Y,
Zhong G, Peng X and Zhang C: Heterogeneous pattern of gene
expression driven by TTN mutation is involved in the construction
of a prognosis model of lung squamous cell carcinoma. Front Oncol.
13:9165682023. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen R, Yao Z and Jiang L: Construction
and validation of a TTN mutation associated immune prognostic model
for evaluating immune microenvironment and outcomes of gastric
cancer: An observational study. Medicine (Baltimore).
103:e389792024. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mayakonda A, Lin DC, Assenov Y, Plass C
and Koeffler HP: Maftools: Efficient and comprehensive analysis of
somatic variants in cancer. Genome Res. 28:1747–1756. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Robinson MD, McCarthy DJ and Smyth GK:
edgeR: A bioconductor package for differential expression analysis
of digital gene expression data. Bioinformatics. 26:139–140. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Maeser D, Gruener RF and Huang RS:
oncoPredict: An R package for predicting in vivo or cancer patient
drug response and biomarkers from cell line screening data. Brief
Bioinform. 22:bbab2602021. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ruiz-Villalba A, Ruijter JM and van den
Hoff MJB: Use and misuse of Cq in qPCR data analysis and
reporting. Life (Basel). 11:4962021.PubMed/NCBI
|
|
34
|
Lei S, Cao W, Zeng Z, Zhang Z, Jin B, Tian
Q, Wu Y, Zhang T, Li D, Hu C, et al: JUND/linc00976 promotes
cholangiocarcinoma progression and metastasis, inhibits ferroptosis
by regulating the miR-3202/GPX4 axis. Cell Death Dis. 13:9672022.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chen X, Li J, Kang R, Klionsky DJ and Tang
D: Ferroptosis: Machinery and regulation. Autophagy. 17:2054–2081.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liang D, Feng Y, Zandkarimi F, Wang H,
Zhang Z, Kim J, Cai Y, Gu W, Stockwell BR and Jiang X: Ferroptosis
surveillance independent of GPX4 and differentially regulated by
sex hormones. Cell. 186:2748–2764.e22. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Propper DJ, Gao F, Saunders MP, Sarker D,
Hartley JA, Spanswick VJ, Lowe HL, Hackett LD, Ng TT, Barber PR, et
al: PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3
signalling, combined with FOLFIRI: A phase I/II study to determine
the importance of schedule and activity in colorectal cancer. Br J
Cancer. 128:245–254. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Pereira M and Vale N: Repurposing alone
and in combination of the antiviral saquinavir with 5-fluorouracil
in prostate and lung cancer cells. Int J Mol Sci. 23:122402022.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Guo J, Yu Z, Sun D, Zou Y, Liu Y and Huang
L: Two nanoformulations induce reactive oxygen species and
immunogenetic cell death for synergistic chemo-immunotherapy
eradicating colorectal cancer and hepatocellular carcinoma. Mol
Cancer. 20:102021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yuan J, Khan SU, Yan J, Lu J, Yang C and
Tong Q: Baicalin enhances the efficacy of 5-fluorouracil in gastric
cancer by promoting ROS-mediated ferroptosis. Biomed Pharmacother.
164:1149862023. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lin J, Bjørk PK, Kolte MV, Poulsen E,
Dedic E, Drace T, Andersen SU, Nadzieja M, Liu H, Castillo-Michel
H, et al: Zinc mediates control of nitrogen fixation via
transcription factor filamentation. Nature. 631:164–169. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Jomova K, Makova M, Alomar SY, Alwasel SH,
Nepovimova E, Kuca K, Rhodes CJ and Valko M: Essential metals in
health and disease. Chem Biol Interact. 367:1101732022. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Luan M, Feng Z, Zhu W, Xing Y, Ma X, Zhu
J, Wang Y and Jia Y: Mechanism of metal ion-induced cell death in
gastrointestinal cancer. Biomed Pharmacother. 174:1165742024.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Sun X, Zhang Y, Li J, Park KS, Han K, Zhou
X, Xu Y, Nam J, Xu J, Shi X, et al: Amplifying STING activation by
cyclic dinucleotide-manganese particles for local and systemic
cancer metalloimmunotherapy. Nat Nanotechnol. 16:1260–1270. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Forner A, Reig M and Bruix J:
Hepatocellular carcinoma. Lancet. 391:1301–1314. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Vogel A, Meyer T, Sapisochin G, Salem R
and Saborowski A: Hepatocellular carcinoma. Lancet. 400:1345–1362.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Sun Y, Wu P, Zhang Z, Wang Z, Zhou K, Song
M, Ji Y, Zang F, Lou L, Rao K, et al: Integrated multi-omics
profiling to dissect the spatiotemporal evolution of metastatic
hepatocellular carcinoma. Cancer Cell. 42:135–156.e17. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Garcia-Lezana T, Lopez-Canovas JL and
Villanueva A: Signaling pathways in hepatocellular carcinoma. Adv
Cancer Res. 149:63–101. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Cheng X, Yin H, Fu J, Chen C, An J, Guan
J, Duan R, Li H and Shen H: Aggregate analysis based on TCGA: TTN
missense mutation correlates with favorable prognosis in lung
squamous cell carcinoma. J Cancer Res Clin Oncol. 145:1027–1035.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Jiang X, Stockwell BR and Conrad M:
Ferroptosis: Mechanisms, biology and role in disease. Nat Rev Mol
Cell Biol. 22:266–282. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zhang C, Liu X, Jin S, Chen Y and Guo R:
Ferroptosis in cancer therapy: A novel approach to reversing drug
resistance. Mol Cancer. 21:472022. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Lee SH, Oh J, Lee ST, Won D, Kim S, Choi
HK, Kim SJ, Han H, Yoon M, Choi JR, et al: Generation of a human
induced pluripotent stem cell line YCMi004-A from a patient with
dilated cardiomyopathy carrying a protein-truncating mutation of
the titin gene and its differentiation towards cardiomyocytes. Stem
Cell Res. 59:1026292022. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Linke WA and Hamdani N: Gigantic business:
Titin properties and function through thick and thin. Circ Res.
114:1052–1068. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Hinson JT, Chopra A, Nafissi N, Polacheck
WJ, Benson CC, Swist S, Gorham J, Yang L, Schafer S, Sheng CC, et
al: HEART DISEASE. Titin mutations in iPS cells define sarcomere
insufficiency as a cause of dilated cardiomyopathy. Science.
349:982–986. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Richardson DR and Ponka P: The molecular
mechanisms of the metabolism and transport of iron in normal and
neoplastic cells. Biochim Biophys Acta. 1331:1–40. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Hassannia B, Vandenabeele P and Vanden
Berghe T: Targeting ferroptosis to iron out cancer. Cancer Cell.
35:830–849. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Zou Y, Palte MJ, Deik AA, Li H, Eaton JK,
Wang W, Tseng YY, Deasy R, Kost-Alimova M, Dančík V, et al: A
GPX4-dependent cancer cell state underlies the clear-cell
morphology and confers sensitivity to ferroptosis. Nat Commun.
10:16172019. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Yang WS, SriRamaratnam R, Welsch ME,
Shimada K, Skouta R, Viswanathan VS, Cheah JH, Clemons PA, Shamji
AF, Clish CB, et al: Regulation of ferroptotic cancer cell death by
GPX4. Cell. 156:317–331. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Conrad M and Pratt DA: The chemical basis
of ferroptosis. Nat Chem Biol. 15:1137–1147. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Li SH, Mei J, Cheng Y, Li Q, Wang QX, Fang
CK, Lei QC, Huang HK, Cao MR, Luo R, et al: Postoperative adjuvant
hepatic arterial infusion chemotherapy With FOLFOX in
hepatocellular carcinoma with microvascular invasion: A
multicenter, phase III, randomized study. J Clin Oncol.
41:1898–1908. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Longley DB, Harkin DP and Johnston PG:
5-fluorouracil: Mechanisms of action and clinical strategies. Nat
Rev Cancer. 3:330–338. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Herman DS, Lam L, Taylor MR, Wang L,
Teekakirikul P, Christodoulou D, Conner L, DePalma SR, McDonough B,
Sparks E, et al: Truncations of titin causing dilated
cardiomyopathy. N Engl J Med. 366:619–628. 2012. View Article : Google Scholar : PubMed/NCBI
|
